



Corrigendum

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]



Sara Valpione ^{a,b}, Matteo S. Carlino ^{c,d}, Johanna Mangana ^e, Meghan J. Mooradian ^f, Grant McArthur ^g, Dirk Schadendorf ^h, Axel Hauschild ⁱ, Alexander M. Menzies ^{c,j}, Ana Arance ^k, Paolo A. Ascierto ^l, AnnaMaria Di Giacomo ^m, Francesco de Rosa ⁿ, James Larkin ^o, John J. Park ^{c,d}, Simone M. Goldinger ^e, Ryan J. Sullivan ^f, Wen Xu ^g, Elisabeth Livingstone ^h, Michael Weichenthal ⁱ, Rajat Rai ^c, Lydia Gaba ^k, Georgina V. Long ^{c,j}, Paul Lorigan ^{a,*}

^a The Christie NHS Foundation Trust, University of Manchester, Manchester, UK

^b CRUK Manchester Institute, Manchester, UK

^c Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia

^d Westmead and Blacktown Hospitals, Westmead, Australia

^e University Hospital of Zurich, Zurich, Switzerland

^f Massachusetts General Hospital, Cancer Center, Boston, MA, USA

^g Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

^h University Hospital Essen, Essen and German Cancer Consortium, Germany

ⁱ Schleswig-Holstein University Hospital, Kiel, Germany

^j Royal North Shore and Mater Hospitals, Australia

^k Hospital Clínic de Barcelona, Barcelona, Spain

^l Istituto Nazionale Tumori “Fondazione G. Pascale”-IRCCS, Naples, Italy

^m Medical Oncology and Immunotherapy University Hospital of Siena, Siena, Italy

ⁿ IRCCS e IRST (Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori), Meldola, Italy

^o The Royal Marsden NHS Foundation Trust, London, UK

The Authors regret that there was a typo in the percentage of response groups in the abstract and main text. The 3rd sentence in the abstract should read:

“The RR to rechallenge with BRAFi ± MEKi was 43.3%: complete response (CR) 2.6%, partial response (PR) 40.7%, stable disease (SD) 24.8% and progressive disease 31.9%, 3 missing.”

The 15th sentence in the abstract should read:

“The overall RR to BRAFi rechallenge was 43.3% for evaluable patients: CR in 3 patients (2.6%), PR in 46 (40.7%), SD in 28 (24.8%), PD in 36 (31.9%) and data missing in 3 patients.”

The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.ejca.2017.12.007>.

The present study was partially presented at ASCO 2017 (abstract 9512).

* Corresponding author: University of Manchester and Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester, M20 4BX, UK. Fax: +44 (0) 161 446 3299.

E-mail address: paul.lorigan@christie.nhs.uk (P. Lorigan).

<https://doi.org/10.1016/j.ejca.2018.02.001>

0959-8049/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).